Search

Your search keyword '"Skoetz, N."' showing total 415 results
Start Over Author "Skoetz, N."
415 results on '"Skoetz, N."'

5. The clinical utility and epidemiological impact of self-testing for SARS-CoV-2 using antigen detecting diagnostics: a systematic review and meta-analysis

Author

Brümmer, LE, Zorger, AM, Worbes, K, McGrath, S, Erdmann, C, Tolle, H, Katzenschlager, S, Yerlikaya, S, Grilli, M, Pollock, NR, Erkosar, B, Mace, A, Ongarello, S, Johnson, CC, Cunningham, J, Sacks, JA, Skoetz, N, Lee, RA, Denkinger, CM, Brümmer, LE, Zorger, AM, Worbes, K, McGrath, S, Erdmann, C, Tolle, H, Katzenschlager, S, Yerlikaya, S, Grilli, M, Pollock, NR, Erkosar, B, Mace, A, Ongarello, S, Johnson, CC, Cunningham, J, Sacks, JA, Skoetz, N, Lee, RA, and Denkinger, CM

Published
2024

6. Resilienz der Gesundheitsforschung als Voraussetzung für Resilienz der Gesundheitsversorgung - das Infrastrukturkonzept 'PREparedness and PAndemic REsponse in Deutschland' (PREPARED) des Netzwerks Universitätsmedizin

Author

Hoffmann, J, Lang, C, Scheithauer, S, Fenz, D, Berens, M, Panchyrz, I, Harst, L, Adorjan, K, Apfelbacher, C, Ciesek, S, Denkinger, C, Drosten, C, Geffers, C, Geraedts, M, Greve, M, Haier, J, Hecker, R, Hoffmann, W, Karch, A, Koch, T, Krefting, D, Lieb, K, Meerpohl, J, Menk, M, Rehfuess, E, Skoetz, N, Sopka, S, Schildmann, J, Taddicken, M, van den Berg, N, von Lengerke, T, Winkler, E, Schmitt, J, PREPARED Study Group, Hoffmann, J, Lang, C, Scheithauer, S, Fenz, D, Berens, M, Panchyrz, I, Harst, L, Adorjan, K, Apfelbacher, C, Ciesek, S, Denkinger, C, Drosten, C, Geffers, C, Geraedts, M, Greve, M, Haier, J, Hecker, R, Hoffmann, W, Karch, A, Koch, T, Krefting, D, Lieb, K, Meerpohl, J, Menk, M, Rehfuess, E, Skoetz, N, Sopka, S, Schildmann, J, Taddicken, M, van den Berg, N, von Lengerke, T, Winkler, E, Schmitt, J, and PREPARED Study Group

Published
2024

9. Physical interventions for people with Parkinson's disease: results from a Cochrane systematic review and network meta-analysis

Author

Ernst, M., primary, Folkerts, A.-K., additional, Roheger, M., additional, Chakraverty, D., additional, Krohm, F., additional, Caro-Valenzuela, J., additional, Gollan, R., additional, Lieker, E., additional, Adams, A., additional, Eggers, C., additional, Monsef, I., additional, Dresen, A., additional, Skoetz, N., additional, and Kalbe, E., additional

Published
2023
Full Text
View/download PDF

10. Determinants of passive antibody efficacy in SARS-CoV-2 infection: a systematic review and meta-analysis

Author

Stadler, E, Chai, KL, Schlub, TE, Cromer, D, Khan, SR, Polizzotto, MN, Kent, SJ, Beecher, C, White, H, Turner, T, Skoetz, N, Estcourt, L, McQuilten, ZK, Wood, EM, Khoury, DS, Davenport, MP, Stadler, E, Chai, KL, Schlub, TE, Cromer, D, Khan, SR, Polizzotto, MN, Kent, SJ, Beecher, C, White, H, Turner, T, Skoetz, N, Estcourt, L, McQuilten, ZK, Wood, EM, Khoury, DS, and Davenport, MP

Abstract

BACKGROUND: Randomised controlled trials of passive antibodies as treatment and prophylaxis for COVID-19 have reported variable efficacy. However, the determinants of efficacy have not been identified. We aimed to assess how the dose and timing of administration affect treatment outcome. METHODS: In this systematic review and meta-analysis, we extracted data from published studies of passive antibody treatment from Jan 1, 2019, to Jan 31, 2023, that were identified by searching multiple databases, including MEDLINE, PubMed, and ClinicalTrials.gov. We included only randomised controlled trials of passive antibody administration for the prevention or treatment of COVID-19. To compare administered antibody dose between different treatments, we used data on in-vitro neutralisation titres to normalise dose by antibody potency. We used mixed-effects regression and model fitting to analyse the relationship between timing, dose and efficacy. FINDINGS: We found 58 randomised controlled trials that investigated passive antibody therapies for the treatment or prevention of COVID-19. Earlier clinical stage at treatment initiation was highly predictive of the efficacy of both monoclonal antibodies (p<0·0001) and convalescent plasma therapy (p=0·030) in preventing progression to subsequent stages, with either prophylaxis or treatment in outpatients showing the greatest effects. For the treatment of outpatients with COVID-19, we found a significant association between the dose administered and efficacy in preventing hospitalisation (relative risk 0·77; p<0·0001). Using this relationship, we predicted that no approved monoclonal antibody was expected to provide more than 30% efficacy against some omicron (B.1.1.529) subvariants, such as BQ.1.1. INTERPRETATION: Early administration before hospitalisation and sufficient doses of passive antibody therapy are crucial to achieving high efficacy in preventing clinical progression. The relationship between dose and efficacy provides a fra

Published
2023

19. Unerwünschte Ereignisse verschiedener Bewegungsangebote für Menschen mit Parkinson

Author

Ernst, M, Folkerts, AK, Roheger, M, Chakraverty, D, Krohm, F, Adams, A, Caro-Valenzuela, J, Gollan, R, Eggers, C, Lieker, E, Monsef, I, Dresen, A, Kalbe, E, Skoetz, N, Ernst, M, Folkerts, AK, Roheger, M, Chakraverty, D, Krohm, F, Adams, A, Caro-Valenzuela, J, Gollan, R, Eggers, C, Lieker, E, Monsef, I, Dresen, A, Kalbe, E, and Skoetz, N

Published
2022

23. Deutschsprachige Übersetzung des PANELVIEW-Instruments zur Evaluierung des Prozesses der Leitlinienentwicklung aus der Perspektive der Leitliniengruppe

Author

Gooßen, K, Becker, M, Mathes, T, Follmann, M, Holtkamp, U, Hostettler, S, Meerpohl, JJ, Nothacker, M, Schaefer, C, Schmidt, S, Schünemann, H, Sommer, I, Tholen, R, Skoetz, N, Pieper, D, Gooßen, K, Becker, M, Mathes, T, Follmann, M, Holtkamp, U, Hostettler, S, Meerpohl, JJ, Nothacker, M, Schaefer, C, Schmidt, S, Schünemann, H, Sommer, I, Tholen, R, Skoetz, N, and Pieper, D

Published
2022

27. Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association

Author

Stemler, J., Jonge, N. de, Skoetz, N., Sinkó, J., Bruggemann, R.J.M., Busca, A., Ben-Ami, R., Ráčil, Z., Piechotta, V., Lewis, R., Cornely, O.A., Stemler, J., Jonge, N. de, Skoetz, N., Sinkó, J., Bruggemann, R.J.M., Busca, A., Ben-Ami, R., Ráčil, Z., Piechotta, V., Lewis, R., and Cornely, O.A.

Abstract

Item does not contain fulltext, On the basis of improved overall survival, treatment guidelines strongly recommend antifungal prophylaxis during remission induction chemotherapy for patients with acute myeloid leukaemia. Many novel targeted agents are metabolised by cytochrome P450, but potential drug-drug interactions (DDIs) and the resulting risk-benefit ratio have not been assessed in clinical trials, leading to uncertainty in clinical management. Consequently, the European Haematology Association commissioned experts in the field of infectious diseases, haematology, oncology, clinical pharmacology, and methodology to develop up-to-date recommendations on the role of antifungal prophylaxis and management of pharmacokinetic DDIs with triazole antifungals. A systematic literature review was performed according to Cochrane methods, and recommendations were developed by use of the Grading of Recommendations Assessment, Development and Evaluation Evidence to Decision framework. We searched MEDLINE, Embase, and Cochrane Library, including Central Register of Controlled Trials, for randomised controlled trials and systematic reviews published from inception to March 10, 2020. We excluded studies that were not published in English. Evidence for any identified novel agent that is active against acute myeloid leukaemia was reviewed for the following outcomes: incidence of invasive fungal disease, prolongation of hospitalisation, days spent in intensive-care unit, mortality due to invasive fungal disease, quality of life, and potential DDIs. Recommendations and consensus statements were compiled for each targeted drug for patients with acute myeloid leukaemia and each specific setting. Evidence-based recommendations were developed for hypomethylating agents, midostaurin, and the venetoclax-hypomethylating agent combination. For all other agents, consensus statements were given for specific therapeutic settings, specifically for the management of patients with relapsed or refractory acute myeloid leukaemia

Published
2022

33. Priorisierung von relevanten Cochrane Review Themen im Bereich Hämatologie

Author

Hirsch, C, Jakob, T, Tomlinson, E, Estcourt, L, Theurich, S, Ocheni, S, Skoetz, N, and Piechotta, V

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Hintergrund/Fragestellung: Die Priorisierung von Forschungsfragen beschränkt sich nicht nur auf die Primärforschung, sondern spielt auch bei der Erstellung systematischer Reviews eine wichtige Rolle. Dadurch wird sichergestellt, dass Ressourcen effektiv genutzt und zur Produktion relevanter[zum vollständigen Text gelangen Sie über die oben angegebene URL], Who cares? – EbM und Transformation im Gesundheitswesen; 22. Jahrestagung des Deutschen Netzwerks Evidenzbasierte Medizin

Published
2021
Full Text
View/download PDF

34. Verfügbarkeit, Preise und Finanzierbarkeit essentieller Krebsmedikamente (EML der WHO) in einkommensschwächeren Ländern: wirkungsvolle Implementierung von Cochrane-Evidenz?

Author

Wagner, C, Skoetz, N, and Piechotta, V

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Hintergrund/Fragestellung: Essentielle Medikamente zielen darauf ab, die vorrangigen Gesundheitsbedürfnisse einer Bevölkerung zu befriedigen, universell verfügbar und erschwinglich zu sein. Die Weltgesundheitsorganisation (WHO) führt ein evidenzbasiertes Modell, die Liste der[zum vollständigen Text gelangen Sie über die oben angegebene URL], Who cares? – EbM und Transformation im Gesundheitswesen; 22. Jahrestagung des Deutschen Netzwerks Evidenzbasierte Medizin

Published
2021
Full Text
View/download PDF

35. Durch Zusammenarbeit mit Nutzern von Cochrane-Evidenz den Wert und die Wirkung von Cochrane-Reviews steigern

Author

Hirsch, C, Jakob, T, Tomlinson, E, Skoetz, N, and Piechotta, V

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Beschreibung: Das Einbeziehen von Stakeholdern (wie Betroffene, Kliniker, politische Entscheidungsträger und relevante Organisationen) in die Priorisierung, Erstellung und Verbreitung von Cochrane-Reviews kann den Wert und die Wirkung der generierten Evidenz steigern. Bei Cochrane sind die einzelnen[zum vollständigen Text gelangen Sie über die oben angegebene URL], Who cares? – EbM und Transformation im Gesundheitswesen; 22. Jahrestagung des Deutschen Netzwerks Evidenzbasierte Medizin

Published
2021
Full Text
View/download PDF

37. Importance of patient participation in Systematic Reviews and its impact on outcomes – experience from a network meta-analysis with breast cancer patients

Author

Jakob, T, Schwesig, G, Jorzick, B, Kerek-Bodden, H, Wöckel, A, and Skoetz, N

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Background/research question: Network meta-analysis (NMA) within Systematic Reviews is a complex method with the intention of comparing different treatment options (e.g. different types of interventions). The aim is to generate a hierarchy of these in terms of efficacy and safety. Particularly [for full text, please go to the a.m. URL], Nützliche patientenrelevante Forschung; 21. Jahrestagung des Deutschen Netzwerks Evidenzbasierte Medizin

Published
2020
Full Text
View/download PDF

38. GRADE Summary of Findings Tabellen und Evidenzprofile richtig verstehen

Author

Goldkuhle, M, Töws, I, Schwingshackl, L, Meerpohl, J, and Skoetz, N

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Beschreibung: GRADE Summary of Findings (SoF) Tabellen und Evidenzprofile dienen der übersichtlichen Darstellung eines Evidenzkörpers im Rahmen von systematischen Übersichtsarbeiten und Leitlinien. Summary of Findings Tabellen sind verpflichtender Teil eines jeden Cochrane Reviews und[zum vollständigen Text gelangen Sie über die oben angegebene URL], Nützliche patientenrelevante Forschung; 21. Jahrestagung des Deutschen Netzwerks Evidenzbasierte Medizin

Published
2020
Full Text
View/download PDF

43. Interdisciplinary guideline on diagnosis, therapy, and follow-up of adult patients with monoclonal gammopathy of undetermined significance or multiple myeloma

Author

Piechotta, V, John, L., Jung, J., Graziani, G., Reinhardt, H., Holtick, U., Semrau, R., Trog, D., Voelker, L. A., Herling, M., Fend, F., Harder, L., Weinhold, N., Kriegsmann, K., Merz, M., Delorme, S., Derlin, T., Raab, M. S., Goede, V, Schubert, M., Hohloch, K., Senf, B., Simon, S. T., Baumann, W., Fetscher, S., Schinke, M., Holtkamp, U., Einsele, H., Engelhardt, M., Goldschmidt, H., Scheid, C., Skoetz, N., Piechotta, V, John, L., Jung, J., Graziani, G., Reinhardt, H., Holtick, U., Semrau, R., Trog, D., Voelker, L. A., Herling, M., Fend, F., Harder, L., Weinhold, N., Kriegsmann, K., Merz, M., Delorme, S., Derlin, T., Raab, M. S., Goede, V, Schubert, M., Hohloch, K., Senf, B., Simon, S. T., Baumann, W., Fetscher, S., Schinke, M., Holtkamp, U., Einsele, H., Engelhardt, M., Goldschmidt, H., Scheid, C., and Skoetz, N.

Published
2020

48. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma

Author

Goldkuhle, M, Ernst, M, Estcourt, LJ, Borchmann, P, Monsef, I, and Skoetz, N

Subjects
Medicine General & Introductory Medical Sciences, hemic and lymphatic diseases, Pharmacology (medical)
Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the benefits, harms and costs of chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphomas (DLBCLs) in accordance with the available body of evidence.

Published
2019
Full Text
View/download PDF

49. Wie werden ausschließlich in Studienregistern veröffentlichte Studien und deren Ergebnisse in aktuellen Cochrane Reviews zu Arzneimitteln berücksichtigt?

Author

Goldkuhle, M, Kaiser, T, and Skoetz, N

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Hintergrund/Fragestellung: Die Suche in Studienregistern ist ein wichtiges Instrument zur Kontrolle von Publikationsbias und Standard bei der Erstellung von Cochrane Reviews. Es ist jedoch unklar, welchen Stellenwert die Studienregistersuche in Cochrane Reviews hat und wie Reviewautoren mit Studien[zum vollständigen Text gelangen Sie über die oben angegebene URL], EbM und Digitale Transformation in der Medizin; 20. Jahrestagung des Deutschen Netzwerks Evidenzbasierte Medizin

Published
2019
Full Text
View/download PDF

50. GRADE Summary of Findings Tabellen und Evidenzprofile: Detaillierte Anleitung für Time-to-event Variablen

Author

Goldkuhle, M, Kreuzberger, N, and Skoetz, N

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Kurze Beschreibung des geplanten Inhalts: Bei der Entwicklung von systematischen Reviews und Leitlinienempfehlungen verwenden viele Autoren die GRADEpro Software zur Bewertung der Evidenz. Die Ergebnisse dieser Bewertungen werden als Summary of Findings (SoF)-Tabellen und Evidenzprofile dargestellt.[zum vollständigen Text gelangen Sie über die oben angegebene URL], EbM und Digitale Transformation in der Medizin; 20. Jahrestagung des Deutschen Netzwerks Evidenzbasierte Medizin

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results